BlackRock Amends Pfizer Stake: Ownership Update Filed
Ticker: PFE · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock just updated its Pfizer holdings, watch for market reaction!**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership stake in Pfizer Inc. as of December 31, 2023. This amendment, number 14, updates BlackRock's previously reported holdings of Pfizer's Common Stock. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in its confidence in Pfizer's future performance, potentially influencing other investors' decisions.
Why It Matters
This filing shows BlackRock's updated position in Pfizer, which can influence market sentiment and provide insight into a major institutional investor's view of the company.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not inherently signal high risk for Pfizer.
Analyst Insight
An investor should note BlackRock's continued interest in Pfizer, but this filing alone doesn't provide enough detail to make a significant investment decision. Further analysis of BlackRock's specific share count changes (which are not detailed in this excerpt) would be necessary.
Key Numbers
- 717081103 — CUSIP Number (identifies Pfizer Inc.'s Common Stock)
- 14 — Amendment Number (indicates this is the 14th amendment to BlackRock's SC 13G filing for Pfizer)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Pfizer Inc. (company) — the subject company whose securities are being reported
- January 26, 2024 (date) — the filing date of the SC 13G/A amendment
- December 31, 2023 (date) — the date of the event which required the filing
- Amendment No: 14 (number) — the specific amendment number for this filing
Forward-Looking Statements
- Other institutional investors may review BlackRock's updated position in Pfizer to inform their own investment strategies. (institutional investors) — medium confidence, target: Q1 2024
- Pfizer's stock price might experience minor fluctuations as the market digests BlackRock's updated ownership information. (Pfizer Inc.) — low confidence, target: January 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., as indicated under '(1)Names of reporting persons. BlackRock,' and in the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What company's securities are the subject of this filing?
The subject company is PFIZER INC, as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC' and '(Name of Issuer) PFIZER INC'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Pfizer Inc. is 717081103, as listed under '(CUSIP Number) 717081103' and 'CUSIP No. 717081103'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding PFIZER INC (PFE).